San Diego-based Viking Therapeutics marked alone as a serious competitor in the weight loss drug market place in February soon after revealing promising knowledge from the mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection As well as in March